Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (303)	5/28/1999 3:08:00 AM
From: CPAMarty	Respond to of 496

Also AMGN has stated publicly that it is going to be filing for a targeted indication this year. I don't think they would mention this if it wasn't some time relatively soon. Any guesses. Parkensons?This should lead to upgrades. According to GLFD's website it probably is Parkensons In April 1998, Amgen selected a preclinical lead compound, called NIL-A, and necessary preclinical work is in progress to determine if this is the appropriate compound to advance to human clinical trials. Based on the preclinical data generated to date, it currently appears that the first clinical indication to be pursued will be in patients with Parkinson's Disease. In September 1998, one month GLP toxicology studies were initiated with NIL-A, as a prelude to future clinical development. guilfordpharm.com